$RDY News

Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript

Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat

Dr. Reddy's Executive During Earnings Conference Call Says Company Has Launched Generic Semaglutide Tablets In India; Not Practical To Move To U.S. Immediately Amid Tariff Environment; Working To Resume Semaglutide Supplies At Earliest; Hoping To Get Semaglutide To Market By November

Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M Estimate

Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk

Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript

Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call

Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

Reported Saturday, Dr. Reddy's Breaks Ground As First Generic Semaglutide Injection Launcher In Canada, Expanding Global GLP-1 Therapy Access

Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

Dr Reddy's Laboratories Q4 EPS $0.03 Misses $0.09 Estimate, Sales $821.821M Miss $866.120M Estimate

Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch GARP Candidate in the Pharmaceuticals Space

Dr. Reddy’s Laboratories (RDY) Announces Rollout of Injectable Semaglutide Under Brand Name Obeda®

Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

Asian Equities Traded in the US as American Depositary Receipts Rising in Wednesday Trading

Asian Equities Traded in US as ADRs Fall in Tuesday Trading